Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Analysis of Relationships Between Prethrombotic States and Cervical Cancer

  • Sun, You-Hong (Department of Gynaecology, Taizhou Second People's Hospital, the Affiliated Hospital of Yangzhou University) ;
  • Cui, Lin (Department of Oncology, Taizhou Second People's Hospital, the Affiliated Hospital of Yangzhou University) ;
  • Chen, Jue (Department of Oncology, Taizhou Second People's Hospital, the Affiliated Hospital of Yangzhou University) ;
  • Wang, Min (Department of Gynaecology, Taizhou Second People's Hospital, the Affiliated Hospital of Yangzhou University) ;
  • Liu, Jian-Jun (Department of Oncology, Taizhou Second People's Hospital, the Affiliated Hospital of Yangzhou University) ;
  • Liu, Xing-Xiang (Department of Oncology, Taizhou Second People's Hospital, the Affiliated Hospital of Yangzhou University) ;
  • Huang, Xin-En (Department of Chemotherapy, Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research)
  • Published : 2015.09.02
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: To analyze the relationship between a prethrombotic state and the occurrence of thrombosis, as well as survival time for patients with cervical cancer. Methods: Patients with first diagnosis of cervical cancer were subgrouped according to FIGO staging, and two D-dimer levels were assessed. According to the results, patients are divided into an observation group (abnormal) and control group (normal). Results: For 106 patients with cervical cancer, 38 with abnormal D-dimer, the abnormal rate is 35.9%, of which stage I accounted for 6.5%, stage II 38.5%, stage III 50%, and stage IV 61.1% (p=0.013); The level of D-dimers in stageI wass $0.87{\pm}0.68ug/ml$, while in stage II it was $1.50{\pm}1.35ug/ml$, stage III $2.60{\pm}1.86ug/ml$ and stage IV $18.6{\pm}53.4ug/ml$ (P=0.031); after follow-up of patients for 2-30 months, the mortality of observation group is 21.1%, while for control group it was 2.94% (p <0.01). In the observation group, survival time was $15.1{\pm}5.8$ months, while for control group it was $21.0{\pm}5.4$ months, the difference between two groups being highly significant (p=0.000). Conclusion: There is a direct correlation between prethrombotic state and the grade malignancy of cervical cancer. The level is positively correlated with clinical stage, and is inversely related to survival time, so that a prethrombotic state could be used to predict the prognosis for patients with cervical cancer.

Keywords

References

  1. Abu Saadeh F, Norris L, O'Toole S, et al (2013). Venous thromboembolism in ovarian cancer: incidence, risk factors and impact on survival. Eur J Obstet Gynecol Reprod Biol, 170, 214-8. https://doi.org/10.1016/j.ejogrb.2013.06.004
  2. Bobek V (2012). Anticoagulant and fibrinolytic drugs-possible agents in treatment of lung cancer? Anticancer Agents Med Chem, 12, 580-8. https://doi.org/10.2174/187152012800617687
  3. Caine GJ, Stonelake PS, Lip GY, et al (2002). The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia, 4, 465-73. https://doi.org/10.1038/sj.neo.7900263
  4. Cao Hongming, Wang Xu, Wang Ze, et al (2013). Risk assessment of venous thrombosis in patients with malignant tumors. Chin J Gerontol, 33, 1465-9.
  5. Colombo N, Carinelli S, Colombo A, et al (2012). Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 23, i27-32.
  6. Cui L, Sun YH, Chen J, et al (2015). Analysis on prethrombotic state in patients with malignant tumors. Asian Pac J Cancer Prev, 16, 5477-82. https://doi.org/10.7314/APJCP.2015.16.13.5477
  7. Farge D, Durant C, Villiers S, et al (2010). Lessons from French National Guidelines on the treatment of venous thrombosis and central venous catheter thrombosis in cancer patients. Thromb Res, 125, S108-16. https://doi.org/10.1016/S0049-3848(10)70027-X
  8. Fidan E, Kavgaci H, Orem A, et al (2012). Thrombin activatable fibrinolysis inhibitor and thrombin-antithrombin-III- complex levels in patients with gastric cancer. Tumour Biol, 33, 1519-25. https://doi.org/10.1007/s13277-012-0403-6
  9. Hu L, Yang H, Su L, et al (2010). Clinical research of the hypercoagulable state in 180 patients with malignant tumor. Med Res Educ, 27, 30-2.
  10. Hu Y, Wu Y, Zou L, et al (2013). Association of coagulation and expression of TAFI with pelvic lymph node metastasis in patients with cervical squamous cell cancer. J Pract Obst Gynecol, 29, 202-5.
  11. Khosa F, Otero HJ, Prevedello LM, et al (2010). Imaging presentation of venous thrombosis in patients with cancer. Am J Roentgenol, 194, 1099-108. https://doi.org/10.2214/AJR.09.2501
  12. Lauw MN, Barco S, Coutinho JM, et al (2013). Cerebral venous thrombosis and thrombophilia: a systematic review and meta-analysis. Semin Thromb Hemost, 39, 913-27. https://doi.org/10.1055/s-0033-1357504
  13. Linkins LA, Bates SM, Lang E, et al (2013). Selective D-D testing for diagnosis of a first suspected episode of deep venous thrombosis: a randomized trial. Ann Intern Med, 158, 93-100. https://doi.org/10.7326/0003-4819-158-2-201301150-00003
  14. Liu C (2013). Application of D-two dimers in the evaluation of prognosis in cervical cancer. Maternal Child Health Care China, 28, 871-3.
  15. Luo C, Fan W, Jiang Y, et al (2014). Risk factors analysis of postoperative venous thromboembolism in early stage cervical carcinoma. Chin J Obstetrics Gynecol Pediatrics (Electronic Edition), 10, 48-52.
  16. Lyman GH, Khorana AA, Falanga A, et al (2007). American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol, 25, 5490-505. https://doi.org/10.1200/JCO.2007.14.1283
  17. Uppal S, Hernandez E, Dutta M, (2012). Prolonged postoperative venous thrombo-embolism prophylaxis is cost-effective in advanced ovarian cancer patients. Gynecol Oncol, 127, 631-7. https://doi.org/10.1016/j.ygyno.2012.08.032
  18. Yu X, Zhang Y, Zhu P, (2013). Changes of plasma fibrinogen and D-dimer levels before and after cervical cancer surgery. Maternal Child Health Care China, 28, 418-20.
  19. Zhang LD, Liu HB, Li YN, et al (2012). Correlation analysis between plasma D-dimer levels and orthopedic trauma severity. Chin Med J (Engl), 125, 3133-6.
  20. Zhang X, Fang J, Chen Y, et a (2014). A Retrospective Analysis of Continuous Detection of Serum D-dimer in Malignancy Dying Patients. Cancer Res Prev Treat, 41, 350-2.
  21. Zhao J, Jiang D (2013). The hypercoagulable state and intervention of malignant tumor. Oncol Prog, 11, 48-52.
  22. Zhao K, Ye J, Wu J, et al (2014). Prognostic significance of coagulation parameters in patients with cervical cancer. J Pract Med, 30, 1941-3.

Cited by

  1. Safety and Efficacy of a Mouth-Rinse with Granulocyte Colony Stimulating Factor in Patients with Chemotherapy-Induced Oral Mucositis vol.17, pp.1, 2016, https://doi.org/10.7314/APJCP.2016.17.1.413
  2. A Clinical Study on Juheli (Recombinant Human Interleukin - 11) in the Second Prevention of Chemotherapy Induced Thrombocytopenia vol.17, pp.2, 2016, https://doi.org/10.7314/APJCP.2016.17.2.485
  3. Cancer cell-derived immunoglobulin G activates platelets by binding to platelet FcγRIIa vol.10, pp.2, 2019, https://doi.org/10.1038/s41419-019-1367-x